Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 2;21(11):e605-e616.
doi: 10.4244/EIJ-D-24-00971.

Impact of pericoronary adipose tissue attenuation on clinical outcomes after percutaneous coronary intervention

Shota Naniwa  1 , Hiroyuki Kawamori  1 , Takayoshi Toba  1 , Takashi Hiromasa  1 , Yoichiro Sugizaki  1 , Satoru Sasaki  1 , Hiroyuki Fujii  1 , Tomoyo Hamana  1 , Yuto Osumi  1 , Tetsuya Yamamoto  1 , Seigo Iwane  1 , Yuki Sakamoto  1 , Koshi Matsuhama  1 , Yuta Fukuishi  1 , Hiroshi Tsunamoto  1 , Kotaro Higuchi  1 , Hiroya Okamoto  1 , Masamichi Iwasaki  2 , Tomofumi Takaya  3 , Shinichiro Yamada  4 , Ken-Ichi Hirata  1 , Hiromasa Otake  1
Affiliations

Impact of pericoronary adipose tissue attenuation on clinical outcomes after percutaneous coronary intervention

Shota Naniwa et al. EuroIntervention. .

Abstract

Background: Pericoronary adipose tissue (PCAT) attenuation, measured using coronary computed tomography angiography (cCTA), is a potential marker of coronary inflammation.

Aims: We aimed to examine the association between coronary inflammation, as assessed by measuring PCAT attenuation before percutaneous coronary intervention (PCI), and clinical outcomes of PCI using current-generation drug-eluting stents (DES).

Methods: We retrospectively studied consecutive patients who underwent cCTA before PCI with current-generation DES. Adverse plaque characteristics, calcified plaque (CP) burden, and PCAT attenuation of the proximal right coronary artery (PCATRCA) were assessed using cCTA. The primary outcome was a patient-oriented composite endpoint (PoCE), including cardiovascular death, non-fatal myocardial infarction, any revascularisation, and stroke.

Results: During a median follow-up of 1,540 days, 77 of 490 patients experienced PoCE. Patients with PoCE had higher PCATRCA (-76.3±6.4 Hounsfield units [HU] vs -82.5±8.1 HU; p<0.001). Multivariable analysis showed that the presence of adverse plaque, greater CP burden and higher PCATRCA were independently associated with PoCE (hazard ratio [HR] 2.05, 95% confidence interval [CI]: 1.26-3.34; p=0.004; HR 1.04, 95% CI: 1.02-1.07; p=0.002; and HR 2.20, 95% CI: 1.63-2.97; p<0.001, respectively). PoCE incidence was 3.9 times higher in patients with high PCATRCA (≥-79.9 HU) than those with low PCATRCA (.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare that are relevant to the content of this article.

References

    1. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–16. - PubMed
    1. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11–22. - PubMed
    1. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340:115–26. - PubMed
    1. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377:1119–31. - PubMed
    1. Antoniades C, Antonopoulos AS, Deanfield J. Imaging residual inflammatory cardiovascular risk. Eur Heart J. 2020;41:748–58. - PubMed

LinkOut - more resources